Wall Street analysts expect that Teladoc Inc (NYSE:TDOC) will post sales of $76.14 million for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Teladoc’s earnings, with estimates ranging from $75.50 million to $76.58 million. Teladoc reported sales of $37.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 103.6%. The business is expected to issue its next earnings results after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Teladoc will report full year sales of $76.14 million for the current financial year, with estimates ranging from $231.70 million to $232.72 million. For the next financial year, analysts expect that the company will report sales of $355.78 million per share, with estimates ranging from $352.90 million to $358.44 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Teladoc.
A number of research firms have recently commented on TDOC. ValuEngine raised shares of Teladoc from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Canaccord Genuity increased their target price on shares of Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Jefferies Group began coverage on shares of Teladoc in a report on Friday, January 26th. They issued a “buy” rating and a $40.00 target price for the company. KeyCorp reissued a “buy” rating and issued a $41.00 target price on shares of Teladoc in a report on Wednesday, January 10th. Finally, Citigroup began coverage on shares of Teladoc in a report on Thursday, January 4th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. Teladoc presently has an average rating of “Buy” and an average price target of $39.43.
Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in Teladoc during the 4th quarter worth approximately $101,000. Ameritas Investment Partners Inc. raised its holdings in Teladoc by 134.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after purchasing an additional 2,707 shares during the last quarter. Montag A & Associates Inc. bought a new position in Teladoc during the 4th quarter worth approximately $200,000. Raymond James Financial Services Advisors Inc. bought a new position in Teladoc during the 2nd quarter worth approximately $202,000. Finally, Buckley Wealth Management LLC bought a new position in Teladoc during the 4th quarter worth approximately $221,000.
Teladoc (NYSE:TDOC) opened at $37.15 on Tuesday. The company has a market cap of $2,119.38, a PE ratio of -25.80 and a beta of 0.49. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc has a fifty-two week low of $19.60 and a fifty-two week high of $38.40.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Teladoc Inc (TDOC) Will Announce Quarterly Sales of $76.14 Million” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/02/20/zacks-analysts-expect-teladoc-inc-tdoc-will-announce-quarterly-sales-of-76-14-million.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.